On 11 November, the European Commission approved a fourth contract with a pharmaceutical company, BioNTech – Pfizer. The contract provides for the initial purchase of 200 million doses on behalf of all EU Member States. Plus an option to purchase up to a further 100 million doses once a vaccine has proven to be